Want to create an interactive transcript for this episode?
Podcast: OncLive® On Air
Episode: FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD
Description: In today’s episode, we had the pleasure of speaking with Lyudmila Bazhenova, MD, about the FDA approval of sunvozertinib (Zegfrovy) for patients with EGFR-mutated metastatic non–small cell lung cancer (NSCLC). Dr Bazhenova is a clinical professor of medicine at the University of California San Diego (UCSD); as well as a medical oncologist at the UCSD Moores Cancer Center.In our exclusive interview, Dr Bazhenova discussed the significance of this approval, key efficacy and safety data from the pivotal the phase 1/2 WU-KONG1B trial (NCT03974022), and how the use of sunvozertinib in the NSCLC treatment paradigm may prop...